^
Association details:
| Biomarker: | CD74-ROS1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | taletrectinib (AB-106) (TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Excerpt:
...Positivity of ROS1 fusion is determined by the local qualified laboratories by using the FISH, RT-PCR or NGS assay, and the subject must provide archival tumor tissue sample for the confirmation by a sponsor-designated central laboratory...
Trial ID:
Source:
Title:
US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors
Published date:
06/26/2020
Excerpt:
Among the 6 RECIST-evaluable ROS1+ NSCLC patients all of whom had progressed on crizotinib and were treated with either 800 mg QD, 1200 mg QD or 400 mg BID, the confirmed ORR is 33% (95%CI: 9.7 – 70.0) and median PFS is 4.1 months (95%CI: 0.5 – 14.2) (Figure 2C, Supplemental Figure 4E and 4F, and Supplemental Table 3). One of these two patients had crizotinib- and ceritinib-refractory ROS1+NSCLC who received 1200 mg QD of taletrectinib and achieved a confirmed partial response of 8 months prior to progression (Figure 3A-B).
DOI:
10.1158/1078-0432.CCR-20-1630
Trial ID:
